On December 09, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium (SABCS) 2024 in San Antonio, Texas, Dec. 10-13, 2024 (Press release, Guardant Health, DEC 9, 2024, View Source [SID1234648957]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Guardant and its research partners will present eight posters, including an SABCS Poster Spotlight featuring the use of the Guardant Reveal test, a tissue-free epigenomic assay, to investigate the dynamics of circulating tumor DNA (ctDNA) during neoadjuvant endocrine therapy in HR+ early breast cancer. Study findings suggest that ctDNA has the potential to provide valuable insights into tumor burden, sensitivity to endocrine therapy, and the emergence of endocrine resistance mutations. The investigators conclude that ctDNA could be a valuable tool in predicting long-term outcomes and in tailoring treatment approaches.
"Working together with our research collaborators, we continue to establish the important role of Guardant’s precision oncology portfolio in informing treatment selection and monitoring for recurrence and therapeutic response," said Craig Eagle, M.D., chief medical officer at Guardant Health. "We look forward to sharing new studies at SABCS that show how Guardant is working with researchers and cancer care teams to improve outcomes for people living with breast cancer."
Guardant Health and collaborator poster presentations at SABCS 2024
Wednesday, December 11 | 7:00-8:30 am | Hemisfair Ballroom 1-2
Abstract
Title
Product
PS7-05
SABCS Poster Spotlight
Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
GuardantINFORM
Wednesday, December 11 | 12:30 – 2:00 pm | Halls 2-3
P1-01-24
Genomic comparison of rapid vs. typical progressors on CDK4/6 inhibitor treatment in advanced breast cancer
GuardantINFORM
P1-05-30
A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer
Guardant Infinity
P1-10-05
Real-world molecular profiling after CDK4/6 inhibition in advanced breast cancer: analysis of the SOLTI-1903 HOPE study
Guardant360 CDx
Wednesday, December 11 | 5:30-7:00 pm | Halls 2-3
P2-05-20
Tissue-free minimal residual disease testing in 2,000 consecutive patients with breast cancer: real-world data and case report
Guardant Reveal
Thursday, December 12 | 7:00-8:30 am | Stars at Night 3-4
PS9-04
SABCS Poster Spotlight
Evaluating racial genomic differences in de novo metastatic breast cancer utilizing ctDNA: results from a large multi-center consortium
Guardant360
PS9-08
SABCS Poster Spotlight
Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC)
Guardant Reveal
Thursday, December 12 | 5:30-7:00 pm | Halls 2-3
P4-01-19
Clinical impact of MRD detection via ctDNA tumor-agnostic assay in early-stage breast cancer patients: a real-world experience
Guardant Reveal
The full abstracts for Guardant Health and a list of all abstracts being presented at SABCS 2024 can be found on the SABCS website.
For information and updates from the conference, visit booth 1424 and follow Guardant Health on LinkedIn, X (Twitter) and Facebook.